DDInter899 DDInter1750
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Tazemetostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Tazemetostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Tazemetostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Tazemetostat {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Tazemetostat may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Tazemetostat may lead to a major life threatening interaction when taken with Caplacizumab